Stop TB Partnership

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points: 
  • Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
  • Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
  • Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
  • BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points: 
  • Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
  • Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
  • Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
  • BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost

Retrieved on: 
Tuesday, September 19, 2023
Partnership, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Bill & Melinda Gates Foundation, TB, Danaher, DHR, Infection, Research, International development, Danaher Corporation, Mark R. Dybul, Incidence, AIDS, Patient, Tuberculosis, United, Stop TB Partnership, USAID, NYSE, World Health Organization, Pharmaceutical industry, Video game, Unitaid, Malaria, Cepheid variable

Enables the Global Fund to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher.

Key Points: 
  • Enables the Global Fund to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher.
  • WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, today announced it will provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at Cepheid's cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria ("the Global Fund") and to less-developed countries eligible for Cepheid's Global Access Program1 to support greater access to high-quality TB testing.
  • By reducing the price of Cepheid's Xpert® MTB/RIF Ultra test cartridge to $7.97, Danaher will be selling at its cost and will earn no profit.
  • The agreement significantly expands a longtime partnership between Cepheid - a Danaher operating company - and the Global Fund to improve access to testing where it matters most.

J&J-Stop TB Partnership Deal a Positive Step but More Is Needed, says AHF

Retrieved on: 
Saturday, July 15, 2023
Infectious Diseases, Pharmaceutical, AIDS, Health, TB, AHF, J&J, COVID-19, Policy, Hope, Stop TB Partnership, Death, HIV, AIDS Healthcare Foundation, Pharmaceutical industry

With Johnson and Johnson (J&J) recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries, AIDS Healthcare Foundation ( AHF ) applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement.

Key Points: 
  • With Johnson and Johnson (J&J) recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries, AIDS Healthcare Foundation ( AHF ) applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement.
  • While the deal is a positive step, AHF agrees with advocates, including Médecins Sans Frontières and others, that this is a short-term solution and urges J&J to do more for other lower-income countries that still lack access.
  • “Tuberculosis kills 1.6 million people annually and remains the leading cause of death for people living with HIV.
  • It is being reported that countries in Eastern Europe and Central Asia, which have some of the world’s highest burden of drug-resistant TB, are left out of the deal.

Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short

Retrieved on: 
Tuesday, January 31, 2023
R, COVID-19, Vaccine, PDP, Tuberculosis, Infection, Stop TB Partnership, Poverty, Pandemic, Mortality, 2021 PDP–Laban dispute, Incidence, Research, Miliary tuberculosis, TB Alliance, Pharmaceutical industry, TB

The report highlights an alarming decline in global investment in product development partnerships (PDPs) for the research and development of medical innovations to address neglected diseases.

Key Points: 
  • The report highlights an alarming decline in global investment in product development partnerships (PDPs) for the research and development of medical innovations to address neglected diseases.
  • PDPs are global leaders in developing new health technologies for Poverty Related Neglected Diseases for which there are scarce commercial incentives.
  • TB Alliance's six-month treatment for drug-resistant TB is a testament to what PDPs can deliver when sufficiently resourced.
  • World leaders must enable the development of the next generation of innovations that can bring devastating diseases like TB to and end.

Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short

Retrieved on: 
Tuesday, January 31, 2023
R, COVID-19, Vaccine, PDP, Tuberculosis, Infection, Stop TB Partnership, Poverty, Pandemic, Mortality, 2021 PDP–Laban dispute, Incidence, Research, Miliary tuberculosis, TB Alliance, Pharmaceutical industry, TB

The report highlights an alarming decline in global investment in product development partnerships (PDPs) for the research and development of medical innovations to address neglected diseases.

Key Points: 
  • The report highlights an alarming decline in global investment in product development partnerships (PDPs) for the research and development of medical innovations to address neglected diseases.
  • PDPs are global leaders in developing new health technologies for Poverty Related Neglected Diseases for which there are scarce commercial incentives.
  • TB Alliance's six-month treatment for drug-resistant TB is a testament to what PDPs can deliver when sufficiently resourced.
  • World leaders must enable the development of the next generation of innovations that can bring devastating diseases like TB to and end.

SystemOne Launches Multi-Instrument Medical Diagnostic Network in Tanzania

Retrieved on: 
Wednesday, November 2, 2022
Technology, Medical Devices, General Health, Infectious Diseases, Science, AIDS, Health, Other Science, Research, Other Technology, Telemedicine, Virtual Medicine, Software, Other Health, Networks, Internet, Hardware, Data Management, Stop TB Partnership, Heart, International development, Infection, CEO, HIV, Community, USAID, Technology, COVID-19, UNOPS, Hepatitis C, National Tuberculosis Institute, Maintenance, TB, United, PATH, Patient, Multimedia, Solution, Communication, Vaccine, Pharmaceutical industry, Aspect, Health, Malaria

SystemOne is launching a multi-device version of its digital backbone for medical diagnostics, Aspect, in Tanzania, to help improve TB diagnostics, reduce time to treatment, and eventually track treatment outcomes and efficacy.

Key Points: 
  • SystemOne is launching a multi-device version of its digital backbone for medical diagnostics, Aspect, in Tanzania, to help improve TB diagnostics, reduce time to treatment, and eventually track treatment outcomes and efficacy.
  • View the full release here: https://www.businesswire.com/news/home/20221102005093/en/
    National staff training on TB data use with the Aspect platform, an upgrade of GxAlert, in Arusha Tanzania in October 2022.
  • Jointly supported by USAID IDDS and USAID Stop TB with technical facilitation by SystemOne.
  • Now SystemOne is adding connectivity to the Truenat device, from Molbio, to the diagnostic network in Tanzania.

AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, May 10, 2022
Drug development, Dulce Base, Safety, Working Group, Infection, Stop TB Partnership, Pharmacokinetics, Research and development, SEC, CEO, Forward-looking statement, Company, Degenerative disease, Patient, Clinical trial, Program, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Total, Fast Track, Research, IPO, Therapy, Board of directors, Mycobacterium, Investment, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, IND, Johnson & Johnson, MAC, R, Goal, Global Alliance, Bacteria, Toxic leukoencephalopathy, Board, COVID-19, QIDP, Nasdaq, AN2, GLOBE, Food, NTM, Administration, Mycobacterium avium complex, PARK, G&A, Pharmaceutical industry, Management

First Quarter & Recent Business Updates:

Key Points: 
  • First Quarter & Recent Business Updates:
    Raised Total of $79.4 Million Through Upsized Initial Public Offering.
  • During the quarter, AN2 Therapeutics appointed Dr. Mel Spigelman to its Board of Directors.
  • Topline results for the ongoing Phase 1 study evaluating epetraborole in renally impaired subjects is expected in the second half of 2022.
  • AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

Retrieved on: 
Thursday, March 24, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, NYSE, Research, SEC, CEO, TB, Tuberculosis, Automation, Solution, Disease, Gold, Molecular diagnostics, Knowledge, IRD, Lymphocyte, QIAGEN, Lyme disease, Pregnancy, Achievement, Death, QuantiFERON, Global, Workflow, U.S. Securities and Exchange Commission, Genetically modified bacteria, Deep Ellum, Dallas, Budget, IGRA, Life, World Health Organization, WHO, DNA, World Tuberculosis Day, QFT, Growth, World, Severe acute respiratory syndrome coronavirus 2, GDF, Review, Interferon, QGEN, Protein, Patient, Infection, LTBI, Partnership, Stop TB Partnership, BCG, Globe, Antigen, RNA, Food, Transmission, US Foods, UNITAID, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Blood, Vaccine, Pharmaceutical industry, Pharma, Insight, Academy

10 million people developed active TB disease in 2020, and they could have been identified and treated before they developed clinical symptoms and transmissible infection.

Key Points: 
  • 10 million people developed active TB disease in 2020, and they could have been identified and treated before they developed clinical symptoms and transmissible infection.
  • Today is World TB Day, a chance to remind the world that most of the 1.5 million annual deaths are avoidable.
  • The milestone of 100 million tests is an important signal on World TB Day.
  • In 2020, the World Health Organization (WHO) estimates that there were 10 million new cases of active TB worldwide and 1.5 million deaths from TB.

AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors

Retrieved on: 
Wednesday, March 16, 2022
Therapy, NTM, Stop TB Partnership, TB Alliance, Sequah Medicine Company, Associate, Novartis, Mount Sinai School, Patient, Dulce Base, Board of directors, Global Alliance, Infection, Multimedia, AN2, Knoll Pharmaceuticals, Safety, Urinary tract infection, BASF, Drug development, Board, Working Group, Research, CEO, Bacteria, Pharmaceutical industry, Mycobacterium

MENLO PARK, Calif., March 16, 2022 /PRNewswire/ --AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Dr. Mel Spigelman, M.D., to its Board of Directors.

Key Points: 
  • MENLO PARK, Calif., March 16, 2022 /PRNewswire/ --AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Dr. Mel Spigelman, M.D., to its Board of Directors.
  • "AN2's lead compound, epetraborole, is in clinical development for NTM lung disease and has the potential to be an important advancement for patients," said Mel Spigelman, M.D.
  • In addition, Dr. Spigelman has served as a board member of multiple publicly listed biotechnology companies, including The Medicines Company (acquired by Novartis).
  • AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.